Logo image of ABNX.PA

ABIONYX PHARMA SA (ABNX.PA) Stock Fundamental Analysis

EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR

1.298  0 (-0.31%)

Fundamental Rating

3

Taking everything into account, ABNX scores 3 out of 10 in our fundamental rating. ABNX was compared to 72 industry peers in the Biotechnology industry. The financial health of ABNX is average, but there are quite some concerns on its profitability. ABNX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABNX had negative earnings in the past year.
In the past year ABNX has reported a negative cash flow from operations.
In the past 5 years ABNX reported 4 times negative net income.
ABNX had a negative operating cash flow in each of the past 5 years.
ABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M -20M

1.2 Ratios

With a decent Return On Assets value of -21.72%, ABNX is doing good in the industry, outperforming 61.11% of the companies in the same industry.
ABNX has a Return On Equity of -35.54%. This is comparable to the rest of the industry: ABNX outperforms 56.94% of its industry peers.
Industry RankSector Rank
ROA -21.72%
ROE -35.54%
ROIC N/A
ROA(3y)-25.65%
ROA(5y)-15.45%
ROE(3y)-52.54%
ROE(5y)-31.66%
ROIC(3y)N/A
ROIC(5y)N/A
ABNX.PA Yearly ROA, ROE, ROICABNX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

ABNX has a Gross Margin (19.19%) which is in line with its industry peers.
In the last couple of years the Gross Margin of ABNX has declined.
The Profit Margin and Operating Margin are not available for ABNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-32.87%
ABNX.PA Yearly Profit, Operating, Gross MarginsABNX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABNX has more shares outstanding
Compared to 5 years ago, ABNX has more shares outstanding
ABNX has a better debt/assets ratio than last year.
ABNX.PA Yearly Shares OutstandingABNX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ABNX.PA Yearly Total Debt VS Total AssetsABNX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

An Altman-Z score of 4.37 indicates that ABNX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.37, ABNX belongs to the top of the industry, outperforming 86.11% of the companies in the same industry.
ABNX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ABNX (0.25) is better than 63.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 4.37
ROIC/WACCN/A
WACC7.79%
ABNX.PA Yearly LT Debt VS Equity VS FCFABNX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 2.28 indicates that ABNX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.28, ABNX is in line with its industry, outperforming 48.61% of the companies in the same industry.
ABNX has a Quick Ratio of 2.22. This indicates that ABNX is financially healthy and has no problem in meeting its short term obligations.
ABNX has a Quick ratio (2.22) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.22
ABNX.PA Yearly Current Assets VS Current LiabilitesABNX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.15% over the past year.
Looking at the last year, ABNX shows a small growth in Revenue. The Revenue has grown by 2.23% in the last year.
The Revenue has been growing by 92.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)23.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.71%
Revenue 1Y (TTM)2.23%
Revenue growth 3YN/A
Revenue growth 5Y92.84%
Sales Q2Q%10.15%

3.2 Future

Based on estimates for the next years, ABNX will show a small growth in Earnings Per Share. The EPS will grow by 5.27% on average per year.
The Revenue is expected to grow by 37.28% on average over the next years. This is a very strong growth
EPS Next Y22.22%
EPS Next 2Y-8.01%
EPS Next 3Y5.27%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y37.28%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ABNX.PA Yearly Revenue VS EstimatesABNX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
ABNX.PA Yearly EPS VS EstimatesABNX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABNX. In the last year negative earnings were reported.
Also next year ABNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABNX.PA Price Earnings VS Forward Price EarningsABNX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABNX.PA Per share dataABNX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.01%
EPS Next 3Y5.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIONYX PHARMA SA

EPA:ABNX (3/7/2025, 7:00:00 PM)

1.298

0 (-0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners4.67%
Inst Owner ChangeN/A
Ins Owners32.61%
Ins Owner ChangeN/A
Market Cap45.34M
Analysts82.86
Price Target11.73 (803.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.34
P/FCF N/A
P/OCF N/A
P/B 4.8
P/tB 11.35
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.14
BVpS0.27
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.72%
ROE -35.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.19%
FCFM N/A
ROA(3y)-25.65%
ROA(5y)-15.45%
ROE(3y)-52.54%
ROE(5y)-31.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-32.87%
F-Score5
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.95%
Cap/Sales 1.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.22
Altman-Z 4.37
F-Score5
WACC7.79%
ROIC/WACCN/A
Cap/Depr(3y)118.03%
Cap/Depr(5y)205.36%
Cap/Sales(3y)10.24%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.71%
EPS Next Y22.22%
EPS Next 2Y-8.01%
EPS Next 3Y5.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.23%
Revenue growth 3YN/A
Revenue growth 5Y92.84%
Sales Q2Q%10.15%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y37.28%
Revenue Next 5YN/A
EBIT growth 1Y14.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.35%
EBIT Next 3Y-9.86%
EBIT Next 5YN/A
FCF growth 1Y50.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.42%
OCF growth 3YN/A
OCF growth 5YN/A